Literature DB >> 16321988

Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1*15.

James A Traherne1, Lisa F Barcellos, Stephen J Sawcer, Alastair Compston, Patricia P Ramsay, Stephen L Hauser, Jorge R Oksenberg, John Trowsdale.   

Abstract

The major histocompatibility complex human leukocyte antigen (HLA)-DRB1*15 (DR2) haplotype is strongly associated with risk of multiple sclerosis (MS). The primary susceptibility has been localized to only approximately 200 kb encompassing the HLA-DR and -DQ loci. Further dissection of disease association with this region is demanding because of the high levels of linkage disequilibrium (LD). Recently, evidence was obtained for the involvement of a gene, potentially encoding an immune co-receptor, in another DR2-associated inflammatory condition, sarcoidosis. The implicated gene, BTNL2, is adjacent to DR and is in strong LD with HLA-DRB1. This fact, combined with a sequence relationship between BTNL2 and myelin oligodendrocyte glycoprotein, an autoantigen associated with MS, makes the gene an attractive candidate. To determine whether BTNL2 contributes to MS, we genotyped 1136 well-characterized MS families from the UK and the USA, as well as an African-American case-control data set, making this among the largest genetic studies in MS. Family-based and case-control association studies were performed for the BTNL2 and HLA-DRB1 loci. In all family data sets, the protein-truncating allele of BTNL2, implicated in sarcoidosis, was significantly over-transmitted to cases (combined data sets: global P=2.4x10(-11)). Given that the protein-truncating allele of BTNL2 virtually always occurred with DRB1*15, an effect could only be tested in DRB1*15-negative individuals or pedigrees. However, despite adequate power to detect an independent association, no difference in transmission of BTNL2 alleles or genotypes was observed in DRB1*15-negative individuals with MS. Conditional logistic regression modeling also strongly supported the conclusion that BTNL2 does not confer additional disease risk. The association of BTNL2 with MS observed in the African-American data set was also secondary to the primary DRB1*15 association.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16321988     DOI: 10.1093/hmg/ddi436

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  11 in total

1.  Multifactor dimensionality reduction reveals gene-gene interactions associated with multiple sclerosis susceptibility in African Americans.

Authors:  D Brassat; A A Motsinger; S J Caillier; H A Erlich; K Walker; L L Steiner; B A C Cree; L F Barcellos; M A Pericak-Vance; S Schmidt; S Gregory; S L Hauser; J L Haines; J R Oksenberg; M D Ritchie
Journal:  Genes Immun       Date:  2006-04-20       Impact factor: 2.676

2.  PyPop update--a software pipeline for large-scale multilocus population genomics.

Authors:  A K Lancaster; R M Single; O D Solberg; M P Nelson; G Thomson
Journal:  Tissue Antigens       Date:  2007-04

Review 3.  Gatekeepers of intestinal inflammation.

Authors:  Heather A Arnett; Joanne L Viney
Journal:  Inflamm Res       Date:  2010-01       Impact factor: 4.575

4.  Association of a polymorphism of BTN2A1 with chronic kidney disease in individuals with or without hypertension or diabetes mellitus.

Authors:  Tetsuro Yoshida; Kimihiko Kato; Mitsutoshi Oguri; Hideki Horibe; Toshiki Kawamiya; Kiyoshi Yokoi; Tetsuo Fujimaki; Sachiro Watanabe; Kei Satoh; Yukitoshi Aoyagi; Masashi Tanaka; Hiroto Yoshida; Shoji Shinkai; Yoshinori Nozawa; Yoshiji Yamada
Journal:  Exp Ther Med       Date:  2011-01-13       Impact factor: 2.447

5.  Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants.

Authors:  Gideon M Hirschfield; Xiangdong Liu; Chun Xu; Yue Lu; Gang Xie; Yan Lu; Xiangjun Gu; Erin J Walker; Kaiyan Jing; Brian D Juran; Andrew L Mason; Robert P Myers; Kevork M Peltekian; Cameron N Ghent; Catalina Coltescu; Elizabeth J Atkinson; E Jenny Heathcote; Konstantinos N Lazaridis; Christopher I Amos; Katherine A Siminovitch
Journal:  N Engl J Med       Date:  2009-05-20       Impact factor: 91.245

Review 6.  Yin-Yang of costimulation: crucial controls of immune tolerance and function.

Authors:  Roza I Nurieva; Xikui Liu; Chen Dong
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

7.  Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis.

Authors:  Daniel I Chasman; Guillaume Paré; Samia Mora; Jemma C Hopewell; Gina Peloso; Robert Clarke; L Adrienne Cupples; Anders Hamsten; Sekar Kathiresan; Anders Mälarstig; José M Ordovas; Samuli Ripatti; Alex N Parker; Joseph P Miletich; Paul M Ridker
Journal:  PLoS Genet       Date:  2009-11-20       Impact factor: 5.917

8.  Association between protective and deleterious HLA alleles with multiple sclerosis in Central East Sardinia.

Authors:  Roberta Pastorino; Cristina Menni; Monserrata Barca; Luisa Foco; Valeria Saddi; Giovanna Gazzaniga; Raffaela Ferrai; Luca Mascaretti; Frank Dudbridge; Carlo Berzuini; Salvatore Bruno Murgia; Maria Luisa Piras; Anna Ticca; Pier Paolo Bitti; Luisa Bernardinelli
Journal:  PLoS One       Date:  2009-08-05       Impact factor: 3.240

Review 9.  Genetic testing in diffuse parenchymal lung disease.

Authors:  Paolo Spagnolo; Fabrizio Luppi; Stefania Cerri; Luca Richeldi
Journal:  Orphanet J Rare Dis       Date:  2012-10-17       Impact factor: 4.123

Review 10.  Human MHC architecture and evolution: implications for disease association studies.

Authors:  J A Traherne
Journal:  Int J Immunogenet       Date:  2008-04-08       Impact factor: 1.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.